ADVFN ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Hot Features

Icon for alerts Registrieren Sie sich für Echtzeit-Benachrichtigungen, benutzerdefinierte Portfolios und Marktbewegungen.
Intellia Therapeutics Inc

Intellia Therapeutics Inc (NTLA)

17,43
-0,41
(-2,30%)
Beim Schlusskurs: 07 Juli 10:00PM
17,38
-0,05
( -0,29% )
Nach Börsenschluss: 11:02PM

Intellia Therapeutics Inc (NTLA) Aktie

Stärken Sie Ihr Portfolio: Diskussionen in Echtzeit und umsetzbare Handelsideen.

Premium

Wichtige Statistiken und Details

Current Price
17,38
( -2,58% )
Gebot
17,37
Fragen
17,43
Volumen
3.169.224
Durchschnittliches Volumen (3 Mio.)
US$ 6.563.397
Finanzvolumen
US$ 54.781.346
16,85 Tagesbereich 18,11
7,95 52-Wochen-Bereich 28,25
Marktkapitalisierung
Unternehmenswert
2,017B
Handelsende
17,84
Handelsbeginn
17,85
Letzte Trade
1
@
17.43
Letzter Handelszeitpunkt
23:04:20
VWAP
17,2854
Erlöse (LTM)
66,09M
Nettogewinn (LTM)
-394,6M
Ausgegebene Aktien
139.722.277
Streubesitz (%)
96,00%
Institutioneller Besitz (%)
76,27%
Dividendenrendite (LTM)
Kurs-Gewinn-Verhältnis
-4,99
Kurs-Umsatz-Verhältnis (KUV)
37,12
Gewinn pro Aktie (EPS)
-3,52
Beta
1,77

Über Intellia Therapeutics Inc

Intellia Therapeutics, Inc. operates as a clinical-stage genome editing company focused on developing potentially curative therapeutics using CRISPR/Cas9-based technologies. The company offers clustered, regularly interspaced short palindromic repeats (“CRISPR”)/CRISPR associated 9 (“Cas9”) technolo... Intellia Therapeutics, Inc. operates as a clinical-stage genome editing company focused on developing potentially curative therapeutics using CRISPR/Cas9-based technologies. The company offers clustered, regularly interspaced short palindromic repeats (“CRISPR”)/CRISPR associated 9 (“Cas9”) technology for genome editing. The company provides a modular platform, to advance in vivo and ex vivo therapies for diseases. The company’s in vivo product candidates include nexiguran ziclumeran, or NTLA-2001 for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema. Additionally, it offers product candidates for the treatment of immuno-oncology and autoimmune diseases, and multiple in vivo programs to address diseases with significant unmet medical need by delivering gene editing therapeutics to organs outside the liver. The company has license and collaboration agreement with AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies; Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of various of B cell-mediated autoimmune diseases; ONK Therapeutics, Ltd. for the development of engineered NK cell therapies to cure patients with cancer; and ReCode Therapeutics, Inc. to develop novel genomic medicines for the treatment of cystic fibrosis. It also has collaboration agreements with Regeneron Pharmaceuticals, Inc., SparingVision SAS, and Rewrite Therapeutics Inc. The company was formerly known as AZRN, Inc. and changed its name to Intellia Therapeutics, Inc. in July 2014. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts. Mehr anzeigen

Sektor
Healthcare
Branche
Biotechnology & Life Sciences
Hauptsitz
Cambridge, United States
Gegründet
2026
Intellia Therapeutics Inc is listed in the Healthcare sector of the NASDAQ with ticker NTLA. The last closing price for Intellia Therapeutics was US$17,84. Over the last year, Intellia Therapeutics shares have traded in a share price range of US$ 7,95 to US$ 28,25.

Intellia Therapeutics currently has 139.722.277 shares in issue. The market capitalisation of Intellia Therapeutics is US$2,43 billion. Intellia Therapeutics has a price to earnings ratio (PE ratio) of -4.99.

Option-Flow Intellia Therapeutics (NTLA)

Gesamtfluss

Bullisch

Nettoprämie

170k

Calls / Puts

400,00%

Käuf. / Verkä.

800,00%

OTM / ITM

42,86%

Sweeps

0,00%

NTLA Neueste Nachrichten

Zeitraum †ÄnderungÄnderung %HandelsbeginnHochNiedrigDurchsch. VolumenVWAP
10.84.8250904704516.5818.4816388451417.3959193CS
43.6126.216412490913.7718.4811.81678043415.02339143CS
122.9620.527045769814.4218.4811.755695470213.9723839CS
267.5476.62601626029.8418.489.77568653413.61543005CS
526.7363.192488262910.6528.257.95589261513.64463612CS
156-21.93-55.787331467839.3146.55.9340057415.11717632CS
260-133.82-88.5052910053151.2180.59375.9247005925.11779784CS

NTLA - Frequently Asked Questions (FAQ)

What is the current Intellia Therapeutics Inc share price?
The current share price of Intellia Therapeutics Inc is US$ 17,38
How many Intellia Therapeutics Inc shares are in issue?
Intellia Therapeutics Inc has 139.722.277 shares in issue
What is the market cap of Intellia Therapeutics Inc?
The market capitalisation of Intellia Therapeutics Inc is USD 2,43B
What is the 1 year trading range for Intellia Therapeutics Inc share price?
Intellia Therapeutics Inc has traded in the range of US$ 7,95 to US$ 28,25 during the past year
What is the PE ratio of Intellia Therapeutics Inc?
The price to earnings ratio of Intellia Therapeutics Inc is -4,99
What is the cash to sales ratio of Intellia Therapeutics Inc?
The cash to sales ratio of Intellia Therapeutics Inc is 37,12
What is the registered address of Intellia Therapeutics Inc?
The registered address for Intellia Therapeutics Inc is 40 Erie Street, Cambridge, Massachusetts, 02139
What is the Intellia Therapeutics Inc website address?
The website address for Intellia Therapeutics Inc is www.intelliatx.com
Which industry sector does Intellia Therapeutics Inc operate in?
Intellia Therapeutics Inc operates in the Biotechnology & Life Sciences sector

NTLA Trades

Mehr

Trades verzögert

Um Echtzeit-Trades zu erhalten, aktualisieren Sie Ihr Konto

Auf Echtzeit aktualisieren
Keine Diskussionen Gefunden.
Neuen Thread Erstellen